Evidence map›Paper›PMID 42644434›Full record

ArticleInternational journal of dermatology2026

Editors Highlights-October 2026.

Lajos Kemény

Abstract readEditorial
In one paragraph

Article in International journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Lajos KeményDepartment of Dermatology and Allergology, University of Szeged, Szeged, Hungary.ORCID https://orcid.org/0000-0002-2119-9501

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment of inflammatory skin diseases has moved from broad immunosuppression toward mechanism-based therapy with targeted biologics and small molecules. Psoriasis exemplifies this shift: interleukin-23 (IL-23)/T helper 17 (Th17) blockade can achieve near-complete clearance, yet persistent tissue-resident memory T cells may sustain disease memory and drive relapse after treatment withdrawal. The papers highlighted in this issue link tissue memory, genotype, treatment durability, and pathway-directed therapy across different skin diseases. Together, they emphasize that precision dermatology must look beyond visible clearance toward biological remission and durable disease control.

Indexed as

Skin DiseasesHumansInterleukin-23PsoriasisTh17 CellsInterleukin-23biologic discontinuationCARD14‐associated papulosquamous eruptiondisease memoryinterleukin‐23phosphodiesterase 4psoriasispyoderma gangrenosumtargeted therapytissue‐resident memory T cells

Identifiers

PMID42644434
PMCPMC13569224

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.